Vermillion (VRML) +14.4% premarket after announcing "positive" top-line results from its OVA1...


Vermillion (VRML) +14.4% premarket after announcing "positive" top-line results from its OVA1 ovarian cancer diagnostic from a clinical study. VRML says OVA1 represents "a new class of software-based diagnostics"; it is the first protein-based, in vitro diagnostic multivariate index assay cleared by the FDA.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs